Georgetown University
Dr. Stephen V. Liu, MD, is a thoracic medical oncologist and an Associate Professor of Medicine at Georgetown University. He is the Director of Thoracic Oncology and the Head of Developmental Therapeutics at the Georgetown University Lombardi Comprehensive Cancer Center. Dr. Liu received his Internal Medicine training at the University of Pennsylvania and completed a fellowship in Hematology and Oncology at the University of Southern California. His research focuses on rational drug development for lung cancer and his work has been published in journals such as the New England Journal of Medicine, Journal of Clinical Oncology, Lancet Oncology and Cancer Discovery. He is also co-host of the official IASLC podcast, Lung Cancer Considered.
Alkermes (Individual(s) Involved: Self; Clinical Condition: Oncology): Grant/Research Support, Grant/Research Support; Amgen (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board, Advisory Board; AstraZeneca (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board, Advisory Board, Consultant, Consultant; Bayer (Individual(s) Involved: Self; Clinical Condition: Oncology): Consultant, Consultant, Grant/Research Support, Grant/Research Support; BeiGene (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board, Advisory Board, Consultant, Consultant; Blueprint Medicines Corporation (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board, Advisory Board, Consultant, Consultant, Grant/Research Support, Grant/Research Support; Boehringer Ingelheim (Individual(s) Involved: Self): Editorial Support, Editorial Support, Other Financial or Material Support, Other Financial or Material Support; Bristol-Myers Squibb (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board, Advisory Board, Grant/Research Support, Grant/Research Support; Catalyst (Individual(s) Involved: Self; Clinical Condition: Oncology): Consultant, Consultant; Daiichi Sankyo (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board, Advisory Board, Consultant, Consultant; Eisai (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board, Advisory Board, Consultant, Consultant; Elevation Oncology (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board, Advisory Board, Consultant, Consultant, Grant/Research Support, Grant/Research Support; Genentech/ Roche (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board, Advisory Board, Consultant, Consultant, Grant/Research Support, Grant/Research Support; Gilead (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board, Advisory Board, Consultant, Consultant, Grant/Research Support, Grant/Research Support; Guardant Health (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board, Advisory Board; Janssen (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board, Advisory Board, Consultant, Consultant; Jazz Pharmaceuticals (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board, Advisory Board; Lilly (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board, Advisory Board, Consultant, Consultant; Merck (Individual(s) Involved: Self; Clinical Condition: Oncology): Consultant, Consultant, Grant/Research Support, Grant/Research Support; Merus (Individual(s) Involved: Self; Clinical Condition: Oncology): Grant/Research Support, Grant/Research Support; Novartis (Individual(s) Involved: Self; Clinical Condition: Oncology): Consultant, Consultant; Nuvalent (Individual(s) Involved: Self; Clinical Condition: Oncology): Grant/Research Support, Grant/Research Support; Pfizer (Individual(s) Involved: Self; Clinical Condition: Oncology): Grant/Research Support, Grant/Research Support; Rain Therapeutics (Individual(s) Involved: Self; Clinical Condition: Oncology): Grant/Research Support, Grant/Research Support; RAPT (Individual(s) Involved: Self; Clinical Condition: Oncology): Grant/Research Support, Grant/Research Support; Regeneron (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board, Advisory Board, Consultant, Consultant; Sanofi US (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board, Advisory Board, Consultant, Consultant; Takeda (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board, Advisory Board, Consultant, Consultant; Turning Point Therapeutics (Individual(s) Involved: Self): Advisory Board, Advisory Board, Consultant, Consultant, Grant/Research Support, Grant/Research Support
Thursday, August 25, 2022
11:35 AM – 12:30 PM
Thursday, August 25, 2022
11:40 AM – 11:55 AM
Thursday, August 25, 2022
12:10 PM – 12:30 PM
Thursday, August 25, 2022
12:40 PM – 1:25 PM
Thursday, August 25, 2022
1:05 PM – 1:25 PM